210 related articles for article (PubMed ID: 7512709)
1. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids.
Elliott K; Minami N; Kolesnikov YA; Pasternak GW; Inturrisi CE
Pain; 1994 Jan; 56(1):69-75. PubMed ID: 7512709
[TBL] [Abstract][Full Text] [Related]
2. Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.
Kolesnikov YA; Pick CG; Ciszewska G; Pasternak GW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5162-6. PubMed ID: 7685116
[TBL] [Abstract][Full Text] [Related]
3. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development.
Elliott K; Kest B; Man A; Kao B; Inturrisi CE
Neuropsychopharmacology; 1995 Dec; 13(4):347-56. PubMed ID: 8747759
[TBL] [Abstract][Full Text] [Related]
4. The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids.
Kest B; McLemore G; Kao B; Inturrisi CE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1249-55. PubMed ID: 9400000
[TBL] [Abstract][Full Text] [Related]
5. The NMDA receptor antagonist MK-801 differentially modulates mu and kappa opioid actions in spinal cord in vitro.
Feng J; Kendig JJ
Pain; 1996 Aug; 66(2-3):343-9. PubMed ID: 8880858
[TBL] [Abstract][Full Text] [Related]
6. Blockade of mu and kappa 1 opioid analgesic tolerance by NPC17742, a novel NMDA antagonist.
Kolesnikov YA; Ferkany J; Pasternak GW
Life Sci; 1993; 53(19):1489-94. PubMed ID: 8412512
[TBL] [Abstract][Full Text] [Related]
7. The role of nitric oxide in the development of morphine tolerance in rat hippocampal slices.
Lue WM; Su MT; Lin WB; Tao PL
Eur J Pharmacol; 1999 Oct; 383(2):129-35. PubMed ID: 10585526
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the role of nitric oxide in kappa-opiate tolerance in mice.
Thorat SN; Reddy PL; Bhargava HN
Brain Res; 1993 Sep; 621(1):171-4. PubMed ID: 7693300
[TBL] [Abstract][Full Text] [Related]
9. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
10. The comparison of effects of processed Aconiti tuber, U50488H and MK-801 on the antinociceptive tolerance to morphine.
Shu H; Hayashida M; Huang W; An K; Chiba S; Hanaoka K; Arita H
J Ethnopharmacol; 2008 Apr; 117(1):158-65. PubMed ID: 18328652
[TBL] [Abstract][Full Text] [Related]
11. Lack of morphine and enkephalin tolerance in 129/SvEv mice: evidence for a NMDA receptor defect.
Kolesnikov Y; Jain S; Wilson R; Pasternak GW
J Pharmacol Exp Ther; 1998 Feb; 284(2):455-9. PubMed ID: 9454784
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
Gistrak MA; Paul D; Hahn EF; Pasternak GW
J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
[TBL] [Abstract][Full Text] [Related]
13. Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50,488H, a kappa-opioid receptor agonist, in the mouse.
Bhargava HN; Thorat SN
Brain Res; 1994 Jun; 649(1-2):111-6. PubMed ID: 7953621
[TBL] [Abstract][Full Text] [Related]
14. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes.
Tiseo PJ; Cheng J; Pasternak GW; Inturrisi CE
J Pharmacol Exp Ther; 1994 Jan; 268(1):195-201. PubMed ID: 8301558
[TBL] [Abstract][Full Text] [Related]
15. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
16. Role of nitric oxide/cyclic GMP in i.c.v. administered beta-endorphin- and (+)-cis-dioxolane-induced antinociception in the mouse.
Xu JY; Tseng LF
Eur J Pharmacol; 1994 Sep; 262(3):223-31. PubMed ID: 7813587
[TBL] [Abstract][Full Text] [Related]
17. ACEA-1328, an NMDA receptor antagonist, increases the potency of morphine and U50,488H in the tail flick test in mice.
Lutfy K; Doan P; Nugyen M; Weber E
Pharmacol Res; 1998 Dec; 38(6):453-60. PubMed ID: 9990654
[TBL] [Abstract][Full Text] [Related]
18. The specific N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 blocks U-50,488, but not morphine antinociception.
Kest B; Marek P; Liebeskind JC
Brain Res; 1992 Aug; 589(1):139-42. PubMed ID: 1422813
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide synthase inhibition blocks tolerance to the analgesic action of kappa-opiate receptor agonist in the rat.
Bhargava HN
Pharmacology; 1994 Apr; 48(4):234-41. PubMed ID: 7513892
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the development of morphine tolerance by U-50,488, an AVP antagonist or MK-801 in the rat hippocampal slice.
Su MT; Lin WB; Lue WM; Cheng CY; Tao PL
Br J Pharmacol; 1998 Feb; 123(4):625-30. PubMed ID: 9517380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
